* product image indicative of product only, actual product may differ in appearance.
Register for your free sample of DOAC-Stop™ at https://www.haematex.com/doac-stop-sample-offer
DOAC-Stop™ is now offered for simplifying diagnostic problems associated with DOACs. DOACs are known to interfere with almost all clotting tests to varying degrees and sometimes patients who need to be tested for underlying coagulation defects may also be on DOACs. Specific antidotes for individual DOACs are being developed for therapeutic use but are not yet widely available for laboratory use. DOAC-Stop™ is first of its kind to extract all types of new Direct Oral Anti-Coagulant (DOACs) including dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban and also argatroban from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism. It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 10 minutes. Unlike therapeutic additives for reversing DOACs it leaves no residual effect. It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results. There is negligible interference with vitamin K antagonist or heparinoid anticoagulants. Plasmas treated with DOAC-Stop™ can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LAC positive results due to DOACs or other agents in testing for lupus anticoagulants. We guarantee a competitive price for our reagents.
1. Exner T, et al. "The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays". International Journal Laboratory Hematology 2020;00:1–8.
2. Favaloro E, et al. "Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa". Thrombosis Research 180 (2019) 10–19
3. Slavic L, et al. "Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban". Clinical and Applied Thrombosis/Hemostasis. 2019; Volume 25: 1-6
4. Zabczyk M, et al. "The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants". De Gruyter Clin Chem Lab Med 2019;
5. Exner T, et al. "Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging agents". Clin Chem Lab Med. 2019; 57: 690-696.
6. Exner T, et al. "Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent". Thromb Res 2019; 179: 69-72
7. Favresse J, et al. "Evaluation of the DOAC Stop procedure to overcome the effect of DOACs on several thrombophilia screening tests". TH Open, 2018; 2: e202-e209.
8. Jacquemin M, et al. "The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays". Int. J. Lab. Haematol. 2018; 40: 442-447.
9. Kopatz WF, et al. "Use of DOAC Stop for elimination of anticoagulants in thrombin generation assays". Thromb. Res. 2018; 170: 97-101.
10. Platton S, Hunt C. "Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban". Int J Lab Haematol. 2018; 1-7.
11. Exner T, et al. "Simple method for removing DOACs from plasma samples" Thromb. Res. 2018; 163: 117-122.